WA Needle Exchanges Report Dramatic Surge in Peptide Injecting

Western Australia’s largest needle and syringe exchange programme has reported a doubling in the number of people accessing its services for synthetic peptide use over the past three years, with a sharp acceleration in the past six to eight months.

Peer Based Harm Reduction (PBHR), a not-for-profit health service operating face-to-face services in Perth and Bunbury, told the ABC on 14 June 2026 that the increase represented a significant shift in who is using injectable peptides and why.

From elite athletes to everyday users

PBHR chief executive Paul Dessauer said the organisation had long served clients using performance- and image-enhancing drugs such as anabolic steroids. But the recent peptide surge was different in both scale and demographics.

“What we’ve seen in the last six to eight months is quite a dramatic and significant increase in the number of people accessing equipment specifically for injecting peptides,” Mr Dessauer told ABC South West WA.

The shift is not limited to needle exchange data. Renae Malan, who owns a personal training business in Bunbury, 170 kilometres south of Perth, said she had noticed increased peptide use within the fitness industry over the past 10 months.

“It goes from probably years ago, just elite athletes using these peptides, to now, I’m seeing the average Joe Blow who wants to feel better, who wants to perform better [using them]… everyone seems to be getting amongst it now,” Ms Malan said.

Social media as the driver

The ABC reported that grey market or unregulated peptides have exploded in popularity as social media influencers promote their supposed benefits for weight loss, anti-ageing, and athletic performance. Platforms including TikTok and Instagram host thousands of videos demonstrating peptide reconstitution, dosing, and injection techniques, often without medical oversight or acknowledgement of regulatory status.

Mr Dessauer said PBHR’s concern centred on peptides purchased in a largely unregulated market, where product quality, sterility, and accurate labelling cannot be verified.

“That’s our concern in terms of this being an emerging public health issue,” he said.

TGA enforcement context

The WA needle exchange data emerged alongside a broader TGA enforcement push. On 20 June 2026, Pharmabiz reported that the TGA had raised concerns over the presence of unapproved peptide products in the Australian market. The regulator has flagged unregulated peptides as a “serious risk” and signalled increased enforcement activity.

The TGA’s position is clear: peptide compounds not listed on the Australian Register of Therapeutic Goods (ARTG) are unapproved therapeutic goods. Supplying them in Australia is an offence under the Therapeutic Goods Act 1989 (Cth), regardless of whether the seller describes them as “research use only” or “not for human consumption.”

What the data means for researchers

The PBHR figures are the first publicly available Australian data quantifying the growth in peptide injecting at a population level. While the service noted that peptides still represent a smaller portion of its total work compared to other illicit drugs, the trajectory is the concern.

For researchers and institutional procurement teams, the data suggests several implications:

Supply chain integrity. As demand shifts from niche athletic use to mainstream consumers, the supply chain is likely to include more operators without quality controls, NATA accreditation, or legitimate sourcing.

Regulatory pressure. Rising public health visibility typically accelerates regulatory response. The TGA’s recent enforcement signals, combined with state-level health alerts and media coverage, suggest a tightening environment.

Access to harm-reduction data. PBHR’s willingness to publish service-level data provides a rare quantitative window into peptide use patterns. Researchers studying the Australian peptide landscape should monitor this data source.

Sources

• ABC South West WA, “WA needle exchanges raise concerns over ‘dramatic’ rise in injectable peptide use,” 14 June 2026
• Pharmabiz, “TGA raises concerns over presence of unapproved peptide products in the market,” 20 June 2026
• ABC News, “Warning issued over counterfeit weight-loss drugs labelled as retatrutide,” 19 June 2026
• Therapeutic Goods Administration, regulatory guidance on unapproved therapeutic goods

---

For educational purposes only. This content is informational and reflects publicly reported developments. It is not legal, medical, or regulatory advice. Consult a qualified professional for compliance questions.